Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven’t responded to oral ...

An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration ...

Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those ...

The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used ...

The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...

Because it is still awaiting approval, Medicare does not typically cover the use of ketamine infusion for treating mental ...

The US FDA has approved the first of its kind ketamine-based nasal spray which is supposed to act as a standalone therapy for ...

Respondents who said they used other drugs recreationally were also likelier to say they used ketamine during the past year ...

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

The Food and Drug Administration (FDA) has approved Spravato, a nasal spray developed by Johnson & Johnson, as a standalone ...

Recreational ketamine use has increased in the United States in recent years, outpacing its rise as a treatment for depression, a new analysis suggests. The hallucinogenic drug — a controlled ...

Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression. Here's what ...